Русский
Efficacy and safety of the russian GLP-1 receptor agonist Quincenta (semaglutide) in patients with type 2 diabetes mellitus in real clinical practice (QUINPROMIS study. Interim data)
DOI: https://dx.doi.org/10.18565/pharmateca.2024.8.54-61
Antsiferov M.B., Koteshkova O.M., Antsiferova D.M., Romashkina L.P., Golubeva Yu.V.
1) Endocrinology Dispensary of the Moscow Healthcare Department, Moscow, Russia; 2) Russian Medical Academy of Continuous Professional Education, Moscow, Russia
Background. Type 2 diabetes mellitus (DM2) is a socially significant disease with a constant growth trend. Therefore, the issues of personalized therapy using innovative drugs are especially relevant given their impact on various factors of the disease pathogenesis. Early prescription of adequate therapy and achievement of the treatment goal according to the indicators of the carbohydrate spectrum of the blood, weight loss are important factors in the prevention of cardiovascular diseases. Continuing research in this area may improve the quality of life of DM 2patients with T2DM.
Objective. Evaluation of the efficacy and safety of using semaglutide (Quincenta®) in the QUINPROMIS study on metabolic status indicators in DM2 patients in routine clinical practice.
Methods. The study included 30 patients of both sexes aged 40 to 65 years inclusive, with a confirmed diagnosis of DM2 lasting at least 6 months, who had not achieved target carbohydrate metabolism control indicators on metformin therapy at a total daily dose of ≥1500 mg, which had to be stable for 8–12 weeks before inclusion in the study. Semaglutide was added to metformin therapy in all patients. Patients underwent standard studies, glycated hemoglobin and blood glucose levels were determined. Body weight, waist and hip circumference were assessed.
Results. Patients included in the study had a relatively short duration of diabetes, were characterized by poor glycemic control, and were obese. During combination therapy, there was a decrease in glycemia from 8,01 to 6,88 mmol/l (P=0,0034), glycated hemoglobin levels from 7,49 to 6,38% (P<0.0001), body weight from 101,1 to 94,27 kg (P=0,0627), waist circumference from 116,33 to 109,23 cm (P=0,0132), hip circumference from 117,64 to 113,2 cm (P=0,0243).
Conclusion. The use of innovative approaches to therapy allowed to improve compensation of carbohydrate metabolism, reduce body weight in DM2 patients during therapy with metformin in combination with semaglutide. Additional experience with the use and confirmation of the safety of semaglutide in DM2 patients was obtained.
Objective. Evaluation of the efficacy and safety of using semaglutide (Quincenta®) in the QUINPROMIS study on metabolic status indicators in DM2 patients in routine clinical practice.
Methods. The study included 30 patients of both sexes aged 40 to 65 years inclusive, with a confirmed diagnosis of DM2 lasting at least 6 months, who had not achieved target carbohydrate metabolism control indicators on metformin therapy at a total daily dose of ≥1500 mg, which had to be stable for 8–12 weeks before inclusion in the study. Semaglutide was added to metformin therapy in all patients. Patients underwent standard studies, glycated hemoglobin and blood glucose levels were determined. Body weight, waist and hip circumference were assessed.
Results. Patients included in the study had a relatively short duration of diabetes, were characterized by poor glycemic control, and were obese. During combination therapy, there was a decrease in glycemia from 8,01 to 6,88 mmol/l (P=0,0034), glycated hemoglobin levels from 7,49 to 6,38% (P<0.0001), body weight from 101,1 to 94,27 kg (P=0,0627), waist circumference from 116,33 to 109,23 cm (P=0,0132), hip circumference from 117,64 to 113,2 cm (P=0,0243).
Conclusion. The use of innovative approaches to therapy allowed to improve compensation of carbohydrate metabolism, reduce body weight in DM2 patients during therapy with metformin in combination with semaglutide. Additional experience with the use and confirmation of the safety of semaglutide in DM2 patients was obtained.
Keywords: non-insulin hypoglycemic agents, semaglutide, treatment algorithms, glucagon-like peptide-1 receptor agonists, type 2 diabetes mellitus
About the Autors
Corresponding author: Daria M. Antsiferova, Endocrinologist, Endocrinology Dispensary of the Moscow Healthcare Department; Postgraduate Student, Department of Endocrinology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; cifrenda@yandex.ru
Similar Articles
